

Issued by JPAC: 16 March 2022

Implementation: To be determined by each Service

Change Notification UK National Blood Services No. 16- 2022

Cervical Dysplasia, Cervical Carcinoma in situ, Cervical Cone Biopsy and Laser Treatment

These changes apply to all the Tissue and Cell Donor Selection Guidelines

Cervical Dysplasia Entry in the Bone Marrow & Peripheral Blood Stem Cell, Cord Blood and Living Tissue Donor Selection Guidelines

Please amend the following sections of this entry:

See:	Cervical Carcinoma in Situ
Obligatory:	<p>Must not donate if:</p> <p>a) Undergoing investigation or treatment.</p> <p>b) Diagnosed with invasive cervical carcinoma.</p>
Discretionary:	<p>a) If the donor had colposcopy treatment for abnormal cervical cells and has been discharged to routine screening, accept. It is not necessary to wait for a normal smear result before donating.</p> <p>b) If only having regular review of smears, accept.</p>
Additional Information:	<p>Cervical screening includes testing for high risk Human Papilloma Virus (HR-HPV). Women who are positive for HR-HPV may be called for routine smear tests at more frequent intervals. They can donate provided they are not undergoing other tests or awaiting colposcopy investigation.</p> <p>Women with abnormal cells on a smear test are triaged according to their risk of developing cervical carcinoma. Women at higher risk will be referred for investigation and treatment via colposcopy.</p> <p>Abnormalities identified at colposcopy include cervical intra epithelial neoplasia (CIN, Grades 1-3) and cervical glandular intra epithelial neoplasia (CGIN). CIN-3 is also known as cervical carcinoma in situ. By definition, patients with CIN or CGIN do not have invasive cervical carcinoma, so can be accepted once treated, fully healed and discharged. There is no need to wait for the results of their next routine smear, usually at 6 months post treatment, unless the donor has been advised that follow up will be necessary at the colposcopy clinic.</p>

<i>Reason for Change:</i>	Updated to clarify the scope of entry, when a donor can be accepted after treatment for cervical dysplasia and the significance of HR-HPV testing.

Cervical Dysplasia Entry in the Deceased Tissue Donor Selection Guidelines

Please amend the following sections of this entry:

<i>See:</i>	Cervical Carcinoma in Situ
<i>Obligatory:</i>	Must not donate if: Diagnosed with invasive cervical carcinoma.
<i>Discretionary:</i>	a) If the donor had colposcopy treatment for abnormal cervical cells and has been discharged to routine screening, accept. It is not necessary to wait for a normal smear result before donating. b) If only having regular review of smears, accept. c) If undergoing investigation or treatment, refer to designated clinical support officer Eyes - Accept
<i>Additional Information:</i>	Cervical screening includes testing for high risk Human Papilloma Virus (HR-HPV). Women who are positive for HR-HPV may be called for routine smear tests at more frequent intervals. They can donate provided they are not undergoing other tests or awaiting colposcopy investigation. Women with abnormal cells on a smear test are triaged according to their risk of developing cervical carcinoma. Women at higher risk will be referred for investigation and treatment via colposcopy. Abnormalities identified at colposcopy include cervical intra epithelial neoplasia (CIN, Grades 1-3) and cervical glandular intra epithelial neoplasia (CGIN). CIN-3 is also known as cervical carcinoma in situ. By definition, patients with CIN or CGIN do not have invasive cervical carcinoma, so can be accepted once treated, fully healed and discharged. There is no need to wait for the results of their next routine smear, usually at 6 months post treatment, unless the donor has been advised that follow up will be necessary at the colposcopy clinic.
<i>Reason for Change:</i>	Updated to clarify the scope of entry, when a donor can be accepted after treatment for cervical dysplasia and the significance of HR-HPV testing.

Cervical Carcinoma in situ Entry in all the Tissue and Cell Donor Selection Guidelines

Delete the current entries and replace with a link to the relevant 'cervical dysplasia' entries. Redirect entry to 'cervical dysplasia' entry at the index level

Cervical Carcinoma in Situ

Please amend the following sections of this entry:

Obligatory:	Must not donate if: Undergoing investigation or treatment.
Discretionary:	a) If investigation and treatment is concluded, accept. b) If just having regular review of smears, accept.

Cervical Cone Biopsy Entry in all the Tissue and Cell Donor Selection Guidelines

Delete the current entries and replace with a link to the relevant 'cervical dysplasia' entries. Redirect entry to 'cervical dysplasia' entry at the index level

Cervical Cone Biopsy

Please amend the following sections of this entry:

See	Cervical Carcinoma in Situ
----------------	---

Laser Treatment Entry in all the Tissue and Cell Donor Selection Guidelines

Laser Treatment

Please amend the following sections of this entry:

<i>Discretionary</i>	b) If for Cervical Carcinoma in Situ, treatment is completed and a follow up smear did not show abnormal cells, accept. see Cervical Dysplasia entry
<i>See if Relevant</i>	Cervical Carcinoma In Situ Cervical Dysplasia

SmacLennan

Dr Sheila MacLennan
Professional Director - Joint UKBTS Professional Advisory Committee
☎ Direct Dial : (0113) 820 8638 ✉ sheila.maclennan@nhsbt.nhs.uk